Analytical Data
-
Gene name
CPLX1
- Application
-
Alternative Names
CPX-I; CPX1; Synaphin-2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14810
-
Expression Region
Met1~Lys134
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CPLX1, or Complexin 1, is a crucial protein involved in synaptic transmission and neurotransmitter release in neurons. It acts as a regulatory protein that bridges the synaptic vesicles and the presynaptic membrane, playing a pivotal role in the precise timing and synchronization of neurotransmitter release during synaptic activity. The study of CPLX1 is particularly significant due to its implications in various neurological disorders, including autism spectrum disorders and schizophrenia, where disruptions in synaptic transmission are often observed. Researchers have focused on characterizing the structure and function of the CPLX1 protein to unravel its role in synaptic regulation and the underlying mechanisms of neurotransmitter release. Understanding the molecular interactions of CPLX1 with other synaptic proteins, such as SNARE complexes, can provide insights into the dynamic processes governing synaptic activity. Additionally, exploring the potential of CPLX1 as a therapeutic target offers promising avenues for developing interventions that may mitigate synaptic dysfunctions associated with neurodevelopmental and psychiatric conditions. Therefore, the investigation of CPLX1 recombinant protein not only enhances our comprehension of synaptic physiology but also contributes to the search for novel therapeutic strategies aimed at restoring normal synaptic function in various mental health disorders.
